Medscape2d
HPV Vaccine ‘Very Promising’ for Nixing Precancerous Lesions
A new HPV vaccine induced regression of precancerous cervical lesions in 50% of patients and led to viral clearance in some ...
GH Research announces primary endpoint met in Phase 2b trial of GH001
PLC reported the primary endpoint was met in a randomized, double-blind, placebo-controlled Phase 2b clinical trial with ...
GlobalData on MSN3d
AstraZeneca’s diabetes drug fails to slow Parkinson’s progression in UCL trial
Researchers concluded that the GLP-1RA showed no ability to slow disease progression in people living with Parkinson’s ...
Healio3d
Blood test may improve decision-making in Alzheimer’s disease
A blood-based biomarker test may be a reliable method for predicting or ruling out Alzheimer’s disease-related pathology and ...
Recursion Presents Phase 2 Data for REC-994 in CCM in Late-Breaking Oral Presentation at the International Stroke Conference
Met primary endpoint of safety and tolerability in CCM patients with no treatment-related discontinuations or Grade 3 adverse ...
Yahoo Finance6d
GH Research Announces Primary Endpoint Met in Phase 2b Trial with GH001 in TRD Demonstrating -15.5 Point Placebo-adjusted MADRS Reduction
Primary endpoint met, GH001 led to an ultra-rapid anti-depressant effect with a significant placebo-adjusted MADRS reduction from baseline of -15.5 on Day 8 (p<0.0001) The majority of the patients ...
Kura Oncology Cancer Study Hits Primary Goal, Lays Out Plans For Phase 3 Studies
Kura Oncology and Kyowa Kirin reported positive Phase 2 results for ziftomenib in AML and plan Phase 3 trials, with an NDA ...
Healio4d
Duravyu for DME meets primary, secondary endpoints in phase 2 trial
Duravyu at two dose levels met its primary endpoint in the treatment of diabetic macular edema in a phase 2 clinical trial, according to a press release from EyePoint Pharmaceuticals.